EGAS00001000387-sc-20131009 - samples
Ontology highlight
ABSTRACT: A potential and very serious side effect of treating IBD with antiTNFa therapies (the current
gold standard) is the development of systemic lupus erythematosis (SLE). This side effect is
rare and unpredictable. Out of several thousand cases having received treatment, the
University of Calgary have accumulated 12 individuals with full phenotyping and novel
serological antibody discovery panel data. We propose to exome sequence these samples in
an effort to identify rare highly-penetrant variants that could be underlying this severe
phenotype.
PROVIDER: EGAD00001000670 | EGA |
REPOSITORIES: EGA
ACCESS DATA